METLIFE INC Form 424B2 November 08, 2013 Table of Contents

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities Offered

4.875% Senior Notes due 2043

 Amount of

 Maximum Aggregate
 Registration

 Offering Price
 Fee(1)(2)

 \$1,000,000,000
 \$128,800

(1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933 as amended.

(2) A registration fee of \$128,800 is due for this offering.

Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-170876

Prospectus Supplement

(To Prospectus Dated November 30, 2010)

\$1,000,000,000

MetLife, Inc.

4.875% Senior Notes due 2043

MetLife, Inc. is offering \$1,000,000,000 aggregate principal amount of its 4.875% Senior Notes due 2043 (the *Senior Notes*). Interest on the Senior Notes will accrue at 4.875% per annum from November 13, 2013. We will pay interest on the Senior Notes semi-annually in arrears on May 13 and November 13 of each year, beginning on May 13, 2014.

The stated maturity of the Senior Notes will be November 13, 2043. The Senior Notes will be redeemable at MetLife, Inc. s option, in whole or in part, at any time and from time to time at a redemption price equal to the greater of 100% of the principal amount to be redeemed plus accrued and unpaid interest thereon to, but excluding, the date of redemption and the Make-Whole Redemption Amount calculated as described in this prospectus supplement.

The Senior Notes will be unsecured obligations of MetLife, Inc. and will rank equally in right of payment with all MetLife, Inc. s existing and future unsecured and unsubordinated indebtedness.

See Risk Factors beginning on page S-11 of this prospectus supplement and the periodic reports MetLife, Inc. files with the Securities and Exchange Commission to read about important factors you should consider before buying the Senior Notes.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of the Senior Notes or passed upon the adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

	Per Senior Note	Total
Price to the Public (1)	99.376%	\$ 993,760,000
Underwriting Discount	0.875%	\$ 8,750,000
Proceeds, before expenses, to MetLife, Inc.	98.501%	\$ 985,010,000

(1) Plus accrued and unpaid interest, if any, from November 13, 2013.

We do not currently intend to list the Senior Notes on any securities exchange. Currently, there is no public market for the Senior Notes.

The Underwriters expect to deliver the Senior Notes, in book-entry form only, through the facilities of The Depository Trust Company (*DTC*) for the accounts of its participants, including Clearstream Banking, *société anonyme*, Luxembourg (*Clearstream Luxembourg*) and/or Euroclear Bank S.A./N.V. (*Euroclear*), on or about November 13, 2013.

Bookrunners

Barclays

Goldman, Sachs & Co.

UBS Investment Bank

Wells Fargo Securities

Co-Managers

Credit Agricole CIBINGLloyds SecuritiesNomura SecuritiesPNC Capital Markets LLCSantanderSOCIETE GENERALEStandard Chartered BankUniCredit Capital MarketsThe Williams Capital Group, L.P.

Junior Co-Managers

Cabrera Capital Markets, LLC

C.L. King & Associates

Drexel Hamilton

Lebenthal Capital Markets Si

Siebert Capital Markets

Prospectus Supplement dated November 7, 2013.

TABLE OF CONTENTS

Prospectus Supplement

	Page
About This Prospectus Supplement	S-3
Where You Can Find More Information	S-3
Special Note Regarding Forward-Looking Statements	S-5
Note Regarding Reliance on Statements in Our Contracts	S-7
<u>Summary</u>	S-8
Risk Factors	S-11
Selected Historical Consolidated Financial Information	S-13
Ratio of Earnings to Fixed Charges	S-16
Use of Proceeds	S-17
<u>Capitalization</u>	S-18
Description of the Senior Notes	S-19
Certain Material U.S. Federal Income Tax Considerations	S-25
Underwriting	S-29
Legal Opinions	S-33
Experts	S-33
Prospectus	
About This Prospectus	1
Risk Factors	1
Note Regarding Forward-Looking Statements	1
Note Regarding Reliance on Statements in Our Contracts	3
Where You Can Find More Information	3
MetLife, Inc.	4
The Trusts	5
<u>Use of Proceeds</u>	6
Ratio of Earnings to Fixed Charges	6
Description of Securities	6
Description of Debt Securities	6
Description of Capital Stock	15
Description of Depositary Shares	21
Description of Warrants	23
Description of Purchase Contracts	23
Description of Units	25
Description of Trust Preferred Securities	26
Description of Guarantees	28
Plan of Distribution	30
Legal Opinions	30
Experts	32
	52

You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. Neither we nor the Underwriters have authorized anyone to provide you with additional or different information. If anyone provided you with additional or different information, you should not rely on it. Neither we nor the Underwriters are making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference, is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates.

Edgar Filing: METLIFE INC - Form 424B2

The Senior Notes are offered for sale in those jurisdictions in the United States, Canada, Europe, Asia and elsewhere where it is lawful to make such offers. The distribution of this prospectus supplement and the accompanying prospectus and the offering or sale of the Senior Notes in some jurisdictions may be restricted by law. Persons into whose possession this prospectus supplement and the accompanying prospectus may not be used for or in connection with an offer or solicitation by any person in any jurisdiction in which that offer or solicitation is not authorized or to any person to whom it is unlawful to make that offer or solicitation. *See* Underwriting Offering Restrictions in this prospectus supplement.

ABOUT THIS PROSPECTUS SUPPLEMENT

You should read this prospectus supplement along with the accompanying prospectus carefully before investing in the Senior Notes. This prospectus supplement contains the terms of the Senior Notes. This prospectus supplement may add, update or change information in the accompanying prospectus. In addition, the information incorporated by reference in the accompanying prospectus may have added, updated or changed information in the accompanying prospectus. If information in this prospectus supplement is inconsistent with any information in the accompanying prospectus (or any information incorporated therein by reference), this prospectus supplement will apply and will supersede such information.

It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus in making your investment decision. You should also read and consider the additional information under the caption Where You Can Find More Information in this prospectus supplement and the accompanying prospectus.

Unless otherwise stated or the context otherwise requires, references in this prospectus supplement to *MetLife*, *we*, *our*, *us*, or *the Company* to MetLife, Inc., a Delaware corporation incorporated in 1999, together with its subsidiaries and affiliates, while references to *MetLife*, *Inc.* refer only to the holding company on an unconsolidated basis.

WHERE YOU CAN FIND MORE INFORMATION

MetLife, Inc. files reports, proxy statements and other information with the Securities and Exchange Commission (the *SEC*). These reports, proxy statements and other information can be read and copied at the SEC s public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference room. The SEC maintains an internet site at www.sec.gov that contains reports, proxy and information statements and other information regarding companies that file electronically with the SEC, including MetLife, Inc. MetLife, Inc. s common stock is listed and trading on the New York Stock Exchange under the symbol MET. These reports, proxy statements and other information can also be read at the offices of the New York Stock Exchange, 11 Wall Street, New York, New York 10005.

The SEC allows incorporation by reference into this prospectus supplement and the accompanying prospectus of information that MetLife, Inc. files with the SEC. This permits MetLife, Inc. to disclose important information to you by referencing these filed documents. Any information referenced this way is considered part of this prospectus supplement and the accompanying prospectus. Information furnished under Item 2.02 and Item 7.01 of MetLife, Inc. s Current Reports on Form 8-K is not incorporated by reference in this prospectus supplement and the accompanying prospectus. MetLife, Inc. incorporates by reference the following documents which have been filed with the SEC:

Annual Report on Form 10-K for the year ended December 31, 2012 (the 2012 Form 10-K)

Quarterly Reports on Form 10-Q for the quarters ended March 31, 2013 (the *First Quarter Form 10-Q*), June 30, 2013 (the *Second Quarter Form 10-Q*) and September 30, 2013 (the *Third Quarter Form 10-Q*);

Definitive Proxy Statement filed on March 22, 2013; and

Current Reports on Form 8-K filed on January 8, 2013, January 14, 2013, February 7, 2013, February 15, 2013, March 4, 2013, March 5, 2013, March 13, 2013, April 22, 2013, April 26, 2013, May 15, 2013, June 26, 2013, July 31, 2013 (only with respect to the Item 5.02 information), August 2, 2013, August 15, 2013, September 6, 2013, September 10, 2013 and September 20, 2013.
MetLife, Inc. incorporates by reference the documents listed above and any future filings made with the SEC in accordance with Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the *Exchange Act*), other than information furnished under Item 2.02 or Item 7.01 of MetLife, Inc. s Current Reports on Form 8-K, until the termination or completion of the offering of the Senior Notes made by this prospectus supplement and the accompanying prospectus. Any reports filed by us with the SEC, other than information furnished under Item 2.02 or Item 7.01 of MetLife, Inc. s Current Reports on Form 8-K, after the date of this prospectus supplement and before the date that the offering of the Senior Notes by means of this prospectus supplement and the accompanying prospectus.

MetLife, Inc. will provide without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus, other than exhibits to those documents, unless those exhibits are specifically incorporated by reference into those documents. Requests should be directed to Investor Relations, MetLife, Inc., 1095 Avenue of the Americas, New York, New York 10036 by electronic mail (metir@metlife.com), or by telephone (212-578-2211). You may also obtain the documents incorporated by reference into this prospectus supplement and the accompanying prospectus at MetLife s website, www.metlife.com. All other information contained on MetLife s website is not a part of this prospectus supplement or the accompanying prospectus.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus supplement and the accompanying prospectus may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as anticipate, estimate, expect, project, intend, plan, believe and other words and terms of similar meaning connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, trends in operations and financial results.

Any or all forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining the actual future results of MetLife. These statements are based on current expectations and the current economic environment. They involve a number of risks and uncertainties that are difficult to predict. These statements are not guarantees of future performance. Actual results could differ materially from those expressed or implied in the forward-looking statements. Risks, uncertainties, and other factors that might cause such differences include the risks, uncertainties and other factors identified in MetLife, Inc. s filings with the SEC. These factors include: (1) difficult conditions in the global capital markets; (2) increased volatility and disruption of the capital and credit markets, which may affect our ability to meet liquidity needs and access capital, including through our credit facilities, generate fee income and market-related revenue and finance statutory reserve requirements and may require us to pledge collateral or make payments related to declines in value of specified assets, including assets supporting risks ceded to certain of our captive reinsurers or hedging arrangements associated with those risks; (3) exposure to financial and capital market risks, including as a result of the disruption in Europe and possible withdrawal of one or more countries from the Euro zone; (4) impact of comprehensive financial services regulation reform on us, as a potential non-bank systemically important financial institution, or otherwise; (5) numerous rulemaking initiatives required or permitted by the Dodd-Frank Wall Street Reform and Consumer Protection Act which may impact how we conduct our business, including those compelling the liquidation of certain financial institutions; (6) regulatory, legislative or tax changes relating to our insurance, international, or other operations that may affect the cost of, or demand for, our products or services, or increase the cost or administrative burdens of providing benefits to employees; (7) adverse results or other consequences from litigation, arbitration or regulatory investigations; (8) potential liquidity and other risks resulting from our participation in a securities lending program and other transactions; (9) investment losses and defaults, and changes to investment valuations; (10) changes in assumptions related to investment valuations, deferred policy acquisition costs, deferred sales inducements, value of business acquired or goodwill; (11) impairments of goodwill and realized losses or market value impairments to illiquid assets; (12) defaults on our mortgage loans; (13) the defaults or deteriorating credit of other financial institutions that could adversely affect us; (14) economic, political, legal, currency and other risks relating to our international operations, including with respect to fluctuations of exchange rates; (15) downgrades in our claims paying ability, financial strength or credit ratings; (16) a deterioration in the experience of the closed block established in connection with the reorganization of Metropolitan Life Insurance Company; (17) availability and effectiveness of reinsurance or indemnification arrangements, as well as any default or failure of counterparties to perform; (18) differences between actual claims experience and underwriting and reserving assumptions; (19) ineffectiveness of risk management policies and procedures; (20) catastrophe losses; (21) increasing cost and limited market capacity for statutory life insurance reserve financings; (22) heightened competition, including with respect to pricing, entry of new competitors, consolidation of distributors, the development of new products by new and existing competitors, and for personnel; (23) exposure to losses related to variable annuity guarantee benefits, including from significant and sustained downturns or extreme volatility in equity markets, reduced interest rates, unanticipated policyholder behavior, mortality or longevity, and the adjustment for nonperformance risk; (24) our ability to address difficulties, unforeseen liabilities, asset impairments, or rating agency actions arising from acquisitions, including our acquisition of American Life Insurance Company and Delaware American Life Insurance Company, and integrating and managing the growth of such acquired businesses, or arising from dispositions of businesses or legal entity reorganizations; (25) the dilutive impact on

our stockholders resulting from the settlement of our outstanding common equity units; (26) regulatory and other restrictions affecting MetLife, Inc. s ability to pay dividends and repurchase common stock; (27) MetLife, Inc. s primary reliance, as a holding company, on dividends from its subsidiaries to meet debt payment obligations and the applicable regulatory restrictions on the ability of the subsidiaries to pay such dividends; (28) the possibility that MetLife, Inc. s Board of Directors may control the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; (29) changes in accounting standards, practices and/or policies; (30) increased expenses relating to pension and postretirement benefit plans, as well as health care and other employee benefits; (31) inability to protect our intellectual property rights or claims of infringement of the intellectual property rights of others; (32) inability to attract and retain sales representatives; (33) provisions of laws and our incorporation documents may delay, deter or prevent takeovers and corporate combinations involving MetLife; (34) the effects of business disruption or economic contraction due to disasters such as terrorist attacks, cyberattacks, other hostilities, or natural catastrophes, including any related impact on the value of our investment portfolio, our disaster recovery systems, cyber- or other information security systems and management continuity planning; (35) the effectiveness of our programs and practices in avoiding giving our associates incentives to take excessive risks; and (36) other risks and uncertainties described from time to time in MetLife, Inc. s filings with the SEC.

MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in reports to the SEC.

NOTE REGARDING RELIANCE ON STATEMENTS IN OUR CONTRACTS

In reviewing the agreements included as exhibits to any of the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about MetLife, Inc., its subsidiaries or affiliates, or the other parties to the agreements. The agreements contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and:

should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

may apply standards of materiality in a way that is different from what may be viewed as material to investors; and

were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time.

SUMMARY

This summary contains basic information about us and the offering. Because it is a summary, it does not contain all of the information that you should consider before purchasing any Senior Notes in the offering. You should read this entire prospectus supplement and the accompanying prospectus carefully, including the sections entitled Risk Factors in this prospectus supplement and the periodic reports MetLife, Inc. files with the SEC, our financial statements and the notes thereto, and the other information incorporated by reference into this prospectus supplement and the accompanying prospectus, before making an investment decision.

MetLife

MetLife is a leading global provider of insurance, annuities and employee benefit programs throughout the United States, Japan, Latin America, Asia, Europe and the Middle East. Through its subsidiaries and affiliates, MetLife offers life insurance, annuities, property & casualty insurance, and other financial services to individuals, as well as group insurance and retirement & savings products and services to corporations and other institutions.

MetLife is organized into six segments, reflecting three broad geographic regions: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; and Latin America (collectively, the *Americas*); Asia; and Europe, the Middle East and Africa (*EMEA*). In addition, the Company reports certain of its results of operations in Corporate & Other, which includes MetLife Home Loans LLC (*MLHL*), the surviving, non-bank entity of the merger of MetLife Bank, National Association (*MetLife Bank*) with and into MLHL during August 2013 (*see* Note 3 of the Notes to the Consolidated Financial Statements included in the 2012 Form 10-K and Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements included in the Second Quarter Form 10-Q for information regarding MetLife Bank s exit from substantially all of its businesses) and other business activities.

On October 1, 2013, MetLife, Inc. completed its previously announced acquisition of Administradora de Fondos de Pensiones Provida S.A. (*Provida*), the largest private pension fund administrator in Chile based on assets under management and number of pension fund contributors. The acquisition of Provida supports the Company's growth strategy in emerging markets and further strengthens the Company's overall position in Chile. *See* Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements included in the Third Quarter Form 10-Q for further information on the acquisition of Provida.

As anticipated, in the third quarter of 2012, the Company continued to realign certain products and businesses among its existing segments to better conform to the way it manages and assesses its business. Management realigned certain individual disability income and property & casualty products, which were previously reported in the Group, Voluntary & Worksite Benefits segment and began reporting such product results in the Retail segment.

Americas. The Americas consists of the following segments:

Retail. The Retail segment offers a broad range of protection products and services and a variety of annuities to individuals and employees of corporations and other institutions, and is organized into two businesses: Life & Other and Annuities. Life & Other insurance products and services include variable life, universal life, term life and whole life products. Additionally, through broker-dealer affiliates, the Company offers a full range of mutual funds and other securities products. Life & Other products and services also include individual disability income products and personal lines property & casualty insurance, including private passenger automobile, homeowners and personal excess liability insurance. Annuities includes a variety of variable and fixed annuities which provide for both asset accumulation and asset distribution needs.

Group, Voluntary & Worksite Benefits. The Group, Voluntary & Worksite Benefits segment offers a broad range of protection products and services to individuals and corporations, as well as other institutions and their respective employees, and is organized into two businesses: Group and Voluntary &

Worksite. Group insurance products and services include variable life, universal life and term life products. Group insurance products and services also include dental, group short- and long-term disability and accidental death & dismemberment coverages. The Voluntary & Worksite business includes personal lines property & casualty insurance, including private passenger automobile, homeowners and personal excess liability insurance offered to employees on a voluntary basis. The Voluntary & Worksite business also includes long-term care, prepaid legal plans and critical illness products.

Corporate Benefit Funding. The Corporate Benefit Funding segment offers a broad range of annuity and investment products, including guaranteed interest products and other stable value products, income annuities, and separate account contracts for the investment management of defined benefit and defined contribution plan assets. This segment also includes certain products to fund postretirement benefits and company-, bank- or trust-owned life insurance used to finance non-qualified benefit programs for executives.

Latin America. The Latin America segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include life insurance, accident and health insurance, group medical, dental, credit insurance, endowment and retirement & savings products written in Latin America. Starting in the first quarter of 2013, the Latin America segment includes U.S. sponsored direct business, comprised of group products sold through sponsoring organizations and affinity groups. Products included are life, dental, group short- and long-term disability, accidental death & dismemberment coverages, property & casualty and critical illness.

Asia. The Asia segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include whole life, term life, variable life, universal life, accident and health insurance, fixed and variable annuities and endowment products.

EMEA. The EMEA segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include life insurance, accident and health insurance, credit insurance, annuities, endowment and retirement & savings products.

Corporate & Other contains the excess capital not allocated to the segments, external integration costs, internal resource costs for associates committed to acquisitions, enterprise-wide strategic initiative restructuring charges, and various start-up and certain run-off businesses. Start-up businesses include expatriate benefits insurance, as well as direct and digital marketing products. Corporate & Other also includes assumed reinsurance of certain variable annuity products from the Company s former operating joint venture in Japan. Under this in-force reinsurance agreement, the Company reinsures living and death benefit guarantees issued in connection with variable annuity products. Additionally, Corporate & Other includes interest expense related to the majority of the Company s outstanding debt and expenses associated with certain legal proceedings and income tax audit issues. Corporate & Other also includes the elimination of intersegment amounts, which generally relate to intersegment loans, which bear interest rates commensurate with related borrowings.

MetLife, Inc. is incorporated under the laws of the State of Delaware. MetLife, Inc. s principal executive offices are located at 200 Park Avenue, New York, New York 10166-0188 and its telephone number is (212) 578-2211.

The Offering

Issuer	MetLife, Inc.
Securities Offered	\$1,000,000,000 aggregate principal amount of 4.875% Senior Notes due 2043 (the <i>Senior Notes</i>).
Maturity Date	November 13, 2043.
Interest Rate	The Senior Notes will bear interest from November 13, 2013 at the rate of 4.875% per year.
Interest Payment Dates	May 13 and November 13 of each year, beginning on May 13, 2014.
Trustee	The Bank of New York Mellon Trust Company, N.A.
Redemption	The Senior Notes will be redeemable at MetLife, Inc. s option, in whole or in part, at any time and from time to time at a redemption price equal to the greater of 100% of the principal amount to be redeemed plus accrued and unpaid interest to, but excluding, the date of redemption and the Make-Whole Redemption Amount calculated as described under Description of the Senior Notes Redemption.
Ranking	The Senior Notes will be unsecured obligations of MetLife, Inc. and will rank equally in right of payment with all of MetLife, Inc. s existing and future unsecured and unsubordinated indebtedness.
Denominations	\$2,000 and integral multiples of \$1,000 in excess thereof.
Use of Proceeds	We estimate that the net proceeds from the sale of the Senior Notes will be approximately \$984,310,000, after deducting the underwriting discounts and commissions and the estimated offering expenses payable by us. We expect to use the net proceeds from the sale of the Senior Notes for general corporate purposes, which may include the repayment, in whole or in part, of \$1.0 billion aggregate principal amount of MetLife, Inc. s 2.375% Senior Notes due 2014 upon their maturity on February 6, 2014 and \$350 million aggregate principal amount of MetLife, Inc. s 5.50% Senior Notes due 2014 upon their maturity on June 15, 2014.
Clearance and Settlement	The Senior Notes will be cleared through DTC, for the accounts of its participants, including Clearstream Luxembourg and/or Euroclear.

Edgar Filing: METLIFE INC - Form 424B2

Listing	The Senior Notes are not, and are not expected to be, listed on any national securities exchange nor included in any automated quotation system.
Governing Law	The State of New York.
Risk Factors	<i>See</i> Risk Factors beginning on page S-11 of this prospectus supplement and the periodic reports MetLife, Inc. files with the SEC to read about important factors you should consider before buying the Senior Notes.

RISK FACTORS

Investing in the Senior Notes involves a high degree of risk. In addition to the other information contained in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, you should consider carefully the following factors relating to us and the Senior Notes before making an investment in the Senior Notes offered hereby. In addition to the risk factors set forth below, please read the information included or incorporated by reference under Risk Factors in the accompanying prospectus, the 2012 Form 10-K, the First Quarter Form 10-Q, the Second Quarter Form 10-Q and the Third Quarter Form 10-Q. If any of the following risks or those incorporated by reference actually occur, our business, results of operations, financial condition, cash flows or prospects could be materially adversely affected, which in turn could adversely affect the market or trading price of the Senior Notes. As a result, you may lose all or part of your original investment. The risks discussed below also include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements.

The Indenture Does Not Limit the Amount of Indebtedness that MetLife, Inc. or Its Subsidiaries May Incur

Neither MetLife, Inc. nor any of its subsidiaries are restricted from incurring additional debt or other liabilities, including additional senior debt securities, under the Indenture (as defined under Description of the Senior Notes). At September 30, 2013, MetLife, Inc. had \$15.4 billion of senior debt outstanding. If we incur additional debt or liabilities, MetLife, Inc. s ability to pay its obligations on the Senior Notes could be adversely affected. We expect that we will from time to time incur additional debt and other liabilities. In addition, MetLife, Inc. is not restricted from paying dividends on or issuing or repurchasing its securities under the Indenture.

There Are No Financial Covenants in the Indenture

There are no financial covenants in the Indenture. You are not protected under the Indenture in the event of a highly leveraged transaction, reorganization, change of control, restructuring, merger or similar transaction that may adversely affect you, except to the limited extent described in the accompanying prospectus under Description of the Debt Securities Consolidation, Merger, Sale of Assets and Other Transactions.

The Senior Notes Are Not Guaranteed by Any of MetLife s Subsidiaries and Are Structurally Subordinated to the Debt and Other Liabilities of Our Subsidiaries, Which Means that Creditors of Our Subsidiaries Will be Paid from Their Assets Before Holders of the Senior Notes Would Have Any Claims to Those Assets

MetLife, Inc. is a holding company and conducts substantially all of its operations through subsidiaries, which means that its ability to meet its obligations on the Senior Notes depends on its ability to receive distributions from these subsidiaries. However, the Senior Notes are obligations exclusively of MetLife, Inc. and are not guaranteed by any of its subsidiaries. As a result, the Senior Notes are structurally subordinated to all debt and other liabilities of MetLife, Inc. s subsidiaries (including liabilities to policyholders and contractholders), which means that creditors of these subsidiaries will be paid from their assets before holders of the Senior Notes would have any claims to those assets. At September 30, 2013, MetLife, Inc. s subsidiaries had \$5.8 billion of total debt outstanding, which includes \$1.9 billion relating to variable interest entities and excludes intercompany liabilities.

An Active After -Market for the Senior Notes May Not Develop

The Senior Notes do not have an established trading market. We cannot assure you that an active after-market for the Senior Notes will develop or be sustained or that holders of the Senior Notes will be able to sell their Senior Notes at favorable prices or at all. Although the Underwriters have indicated to us that they intend to make a market in the Senior Notes, as permitted by applicable laws and regulations, they are not obligated to do so and may discontinue any such market-making at any time without notice. Accordingly, no assurance can be given as to the liquidity of, or trading markets for, the Senior Notes. The Senior Notes are not listed and we do not plan to apply to list the Senior Notes on any securities exchange or to include them in any automated quotation system.

If a Trading Market Does Develop, Changes in Our Credit Ratings or the Debt Markets Could Adversely Affect the Market Price of the Senior Notes

The market price for the Senior Notes depends on many factors, including:

Our credit ratings with major credit rating agencies;

The prevailing interest rates being paid by other companies similar to us;

Our financial condition, financial performance and future prospects; and

The overall condition of the financial markets.

The condition of the financial markets and prevailing interest rates have fluctuated in the past and are likely to fluctuate in the future. Such fluctuations could have an adverse effect on the price of the Senior Notes.

In addition, credit rating agencies continually review their ratings for the companies that they follow, including us. The credit rating agencies also evaluate the insurance industry as a whole and may change their credit rating for us based on their overall view of our industry. A negative change in our rating could have an adverse effect on the price of the Senior Notes.

SELECTED HISTORICAL CONSOLIDATED FINANCIAL INFORMATION

The following tables set forth selected historical consolidated financial information for MetLife. The selected historical consolidated financial information at December 31, 2012 and 2011 and for the years ended December 31, 2012, 2011 and 2010 has been derived from our audited financial statements included in the 2012 Form 10-K and should be read in conjunction with, and is qualified by reference to, Management s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and the related notes included therein. The selected historical consolidated financial information at December 31, 2010, 2009 and 2008 and for the years ended December 31, 2009 and 2008 has been derived from the selected financial data also included in the 2012 Form 10-K and should be read in conjunction with, and is qualified by reference to, Management s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial information at December 31, 2010, 2009 and 2008 and for the years ended December 31, 2009 and 2008 has been derived from the selected financial data also included in the 2012 Form 10-K and should be read in conjunction with, and is qualified by reference to, Management s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and the related notes included therein. The selected historical consolidated financial information at September 30, 2013 and 2012 has been derived from the unaudited interim condensed consolidated financial statements and the related notes included in the Third Quarter Form 10-Q and should be read in conjunction with, and is qualified by reference to, Management s Discussion and Analysis of Financial Condition and Results of Operations and the unaudited interim condensed consolidated financial statements and the related notes included therein. The following consolidated statements of operations and consolidated balance sheet data have been prepared in con

Universal life and investment-type product policy fees 7,034 6,306 8,556 7,806 6,028 5,197 Net investment income 16,385 16,436 21,984 19,585 17,493 14,726 Other revenues 1,446 1,445 1,906 2,532 2,328 2,329 Net investment gains (losses) 339 (152) (352) (867) (408) (2,901) Net derivative gains (losses) (2,866) (604) (1,919) 4,824 (265) (4,866) Total revenues 49,741 50,817 68,150 70,241 52,247 40,642 Expenses Policyholder benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1 1 1 1 1 1 1 1 1	2008 25,604 5,373 16,168 1,585 (2,085) 3,910 50,555
Revenues Premiums \$ 27,403 \$ 27,386 \$ 37,975 \$ 36,361 \$ 27,071 \$ 26,157 \$ Universal life and investment-type product policy fees 7,034 6,306 8,556 7,806 6,028 5,197 Net investment income 16,385 16,436 21,984 19,585 17,493 14,726 Other revenues 1,446 1,445 1,906 2,532 2,328 2,329 Net investment gains (losses) 339 (152) (352) (867) (408) (2,901) Net derivative gains (losses) (2,866) (604) (1,919) 4,824 (265) (4,866) Total revenues 49,741 50,817 68,150 70,241 52,247 40,642 Expenses 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868	5,373 16,168 1,585 (2,085) 3,910
Premiums \$ 27,403 \$ 27,386 \$ 37,975 \$ 36,361 \$ 27,071 \$ 26,157 \$ Universal life and investment-type product policy fees 7,034 6,306 8,556 7,806 6,028 5,197 Net investment income 16,385 16,436 21,984 19,585 17,493 14,726 Other revenues 1,446 1,445 1,906 2,532 2,328 2,329 Net investment gains (losses) 339 (152) (352) (867) (408) (2,901) Net derivative gains (losses) (2,866) (604) (1,919) 4,824 (265) (4,866) Total revenues 49,741 50,817 68,150 70,241 52,247 40,642 Expenses Policyholder benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868	5,373 16,168 1,585 (2,085) 3,910
Universal life and investment-type product policy fees 7,034 6,306 8,556 7,806 6,028 5,197 Net investment income 16,385 16,436 21,984 19,585 17,493 14,726 Other revenues 1,446 1,445 1,906 2,532 2,328 2,329 Net investment gains (losses) 339 (152) (352) (867) (408) (2,901) Net derivative gains (losses) (2,866) (604) (1,919) 4,824 (265) (4,866) Total revenues 49,741 50,817 68,150 70,241 52,247 40,642 Expenses 9 49,741 50,817 68,150 70,241 52,247 40,642 Expenses 9 49,741 50,817 68,150 70,241 52,247 40,642 Expenses 9 5 1,050 1,369 1,446 1,485 1,649 Goodwill er benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,050 1,050 <t< td=""><td>5,373 16,168 1,585 (2,085) 3,910</td></t<>	5,373 16,168 1,585 (2,085) 3,910
Net investment income 16,385 16,436 21,984 19,585 17,493 14,726 Other revenues 1,446 1,445 1,906 2,532 2,328 2,329 Net investment gains (losses) 339 (152) (352) (867) (408) (2,901) Net derivative gains (losses) (2,866) (604) (1,919) 4,824 (265) (4,866) Total revenues 49,741 50,817 68,150 70,241 52,247 40,642 Expenses Policyholder benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 10 12,140 13,341 17,755 18,537 12,927 10,761 Total expenses 46,957 48,898 66,708 61,057 48,518 45,260 Income (loss) from continuing operations be	16,168 1,585 (2,085) 3,910
Other revenues $1,446$ $1,445$ $1,906$ $2,532$ $2,328$ $2,329$ Net investment gains (losses) 339 (152) (352) (867) (408) $(2,901)$ Net derivative gains (losses) $(2,866)$ (604) $(1,919)$ $4,824$ (265) $(4,866)$ Total revenues $49,741$ $50,817$ $68,150$ $70,241$ $52,247$ $40,642$ Expenses $$	1,585 (2,085) 3,910
Net investment gains (losses) 339 (152) (352) (867) (408) (2,901) Net derivative gains (losses) (2,866) (604) (1,919) 4,824 (265) (4,866) Total revenues 49,741 50,817 68,150 70,241 52,247 40,642 Expenses 49,741 50,817 68,150 70,241 52,247 40,642 Expenses 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1	(2,085) 3,910
Net derivative gains (losses) (2,866) (604) (1,919) 4,824 (265) (4,866) Total revenues 49,741 50,817 68,150 70,241 52,247 40,642 Expenses Policyholder benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1 1649 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 4	3,910
Total revenues 49,741 50,817 68,150 70,241 52,247 40,642 Expenses Policyholder benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1,868 0 1 0 0 0 <th< td=""><td></td></th<>	
Expenses Policyholder benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1 1649 1 Other expenses 12,140 13,341 17,755 18,537 12,927 10,761 Total expenses 46,957 48,898 66,708 61,057 48,518 45,260 Income (loss) from continuing operations before provision for 54 54 55 55 55 56	50,555
Policyholder benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1 1 1 1 1 Other expenses 12,140 13,341 17,755 18,537 12,927 10,761 Total expenses 46,957 48,898 66,708 61,057 48,518 45,260 Income (loss) from continuing operations before provision for 5 5 5 5 5 5 5	
Policyholder benefits and claims 27,827 26,958 37,987 35,471 29,187 28,005 Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1 1 1 1 1 Other expenses 12,140 13,341 17,755 18,537 12,927 10,761 Total expenses 46,957 48,898 66,708 61,057 48,518 45,260 Income (loss) from continuing operations before provision for 5 5 5 5 5 5 5	
Interest credited to policyholder account balances 6,036 5,681 7,729 5,603 4,919 4,845 Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1 <td< td=""><td>27,095</td></td<>	27,095
Policyholder dividends 954 1,050 1,369 1,446 1,485 1,649 Goodwill impairment 1,868 1,868 1,868 1,863 1 Other expenses 12,140 13,341 17,755 18,537 12,927 10,761 Total expenses 46,957 48,898 66,708 61,057 48,518 45,260 Income (loss) from continuing operations before provision for 5 5 5 5 5	4,787
Other expenses 12,140 13,341 17,755 18,537 12,927 10,761 Total expenses 46,957 48,898 66,708 61,057 48,518 45,260 Income (loss) from continuing operations before provision for 5 5 5 5 5	1,749
Total expenses46,95748,89866,70861,05748,51845,260Income (loss) from continuing operations before provision for	
Income (loss) from continuing operations before provision for	11,988
	45,619
	4.026
	4,936
Provision for income tax expense (benefit) 308 710 128 2,793 1,110 (2,107)	1,542
Income (loss) from continuing operations, net of income tax 2,476 1,209 1,314 6,391 2,619 (2,511)	3,394
Income (loss) from discontinued operations, net of income tax 1 17 48 24 44 64	(179)
Net income (loss) 2,477 1,226 1,362 6,415 2,663 (2,447)	3,215
Less: Net income (loss) attributable to noncontrolling interests 17 29 38 (8) (4) (36)	66
Net income (loss) attributable to MetLife, Inc. 2,460 1,197 1,324 6,423 2,667 (2,411)	3,149
Less: Preferred stock dividends 91 91 122 122 122 122	125
Preferred stock redemption premium 146	

Net income (loss) available to MetLife, Inc.	s common
shareholders	

\$ 2,369 \$ 1,106 \$ 1,202 \$ 6,155 \$ 2,545 \$ (2,533) \$ 3,024

	Nine Mont Septeml			Years I	Ended Dece	mber 31,	
	2013	2012	2012	2011	2010	2009	2008
			(In millions,	except per	share data)		
EPS Data (1), (2)							
Income (loss) from continuing operations available to MetLife,							
Inc. s common shareholders per common share:							
Basic	\$ 2.15	\$ 1.02	\$ 1.08	\$ 5.79	\$ 2.83	\$ (3.17)	\$ 4.48
Diluted	\$ 2.14	\$ 1.01	\$ 1.08	\$ 5.74	\$ 2.81	\$ (3.17)	\$ 4.43
Income (loss) from discontinued operations per common share:							
Basic	\$	\$ 0.02	\$ 0.04	\$ 0.02	\$ 0.05	\$ 0.08	\$ (0.37)
Diluted	\$	\$ 0.02	\$ 0.04	\$ 0.02	\$ 0.05	\$ 0.08	\$ (0.37)
Net income (loss) available to MetLife, Inc. s common							
shareholders per common share:							
Basic	\$ 2.15	\$ 1.04	\$1.12	\$ 5.81	\$ 2.88	\$ (3.09)	\$ 4.11
Diluted	\$ 2.14	\$ 1.03	\$1.12	\$ 5.76	\$ 2.86	\$ (3.09)	\$ 4.06
Cash dividends declared per common share	\$ 0.735	\$	\$ 0.74	\$ 0.74	\$ 0.74	\$ 0.74	\$ 0.74

	September 30,					
	2013	2012	2011	2010	2009	2008
			(In mill	lions)		
Balance Sheet Data (1)						
Separate account assets (3)	\$ 255,250	\$ 235,393	\$ 203,023	\$ 183,138	\$ 148,854	\$ 120,697
Total assets (3)	\$ 822,643	\$ 836,781	\$ 796,226	\$ 728,249	\$ 537,531	\$ 499,794
Policyholder liabilities and other policy-related						
balances (3), (4)	\$419,352	\$438,191	\$421,267	\$ 399,135	\$ 281,495	\$ 280,351
Short-term debt	\$ 100	\$ 100	\$ 686	\$ 306	\$ 912	\$ 2,659
Long-term debt (3)	\$ 18,252	\$ 19,062	\$ 23,692	\$ 27,586	\$ 13,220	\$ 9,667
Collateral financing arrangements	\$ 4,196	\$ 4,196	\$ 4,647	\$ 5,297	\$ 5,297	\$ 5,192
Junior subordinated debt securities	\$ 3,193	\$ 3,192	\$ 3,192	\$ 3,191	\$ 3,191	\$ 3,758
Separate account liabilities (3)	\$ 255,250	\$ 235,393	\$ 203,023	\$ 183,138	\$ 148,854	\$ 120,697
Accumulated other comprehensive income (loss)	\$ 5,100	\$ 11,397	\$ 6,083	\$ 1,145	\$ (3,049)	\$ (14,512)
Total MetLife, Inc. s stockholders equity	\$ 60,927	\$ 64,453	\$ 57,519	\$ 46,853	\$ 31,336	\$ 21,846
Noncontrolling interests	\$ 341	\$ 384	\$ 370	\$ 365	\$ 371	\$ 249

		ths Ended iber 30,		Years F	Ended Decem	ber 31,	
	2013	2012	2012	2011	2010	2009	2008
Other Data (1), (5)							
Return on MetLife, Inc. s common equity	N/A	N/A	2.0%	12.2%	6.9%	(9.9)%	10.9%
Return on MetLife, Inc. s common equity, excluding							
accumulated other comprehensive income (loss)	N/A	N/A	2.4%	13.2%	7.0%	(7.3)%	9.3%

(1) On November 1, 2010, MetLife, Inc. acquired American Life Insurance Company and Delaware American Life Insurance Company. Results of such acquisition are reflected in the selected financial data since the acquisition date.

(2) For the nine months ended September 30, 2013 and 2012, and the years ended December 31, 2012 and 2010, all shares related to the assumed issuance of shares in settlement of the applicable purchase contracts have been excluded from the calculation of diluted earnings per common share as these assumed shares are anti-dilutive. For the year ended December 31, 2009, shares related to the assumed exercise or issuance of stock-based awards have been excluded from the calculation of diluted earnings per common share, as to include such assumed shares would be anti-dilutive.

(3) Amounts relating to variable interest entities are as follows at:

	ember 30, 2013	2012	December 31, 2011 (In millions)	2010
General account assets	\$ 6,891	\$ 6,692	\$ 7,273	\$ 11,080
Separate account assets	\$ 984	\$	\$	\$
Policyholder liabilities and other policy-related balances	\$ 647	\$	\$	\$
Long-term debt	\$ 1,946	\$ 2,527		